Renal cell cancer: overview of the current therapeutic landscape

Basit Öğe Kaydı
dc.contributor.authorErman, Mustafa
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorBasaran, Mert
dc.contributor.authorBavbek, Sevil
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorCoskun, Ugur
dc.contributor.authorDemir, Gokhan
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzkan, Metin
dc.contributor.authorSevinc, Alper
dc.contributor.authorYalcin, Suayib
dc.date.accessioned2019-10-27T23:08:50Z
dc.date.available2019-10-27T23:08:50Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: The last decade has witnessed dramatic improvements in the diagnosis, classification and treatment of renal cell cancer (RCC). Besides improvements in surgical techniques in early stages, introduction of novel targeted agents has resulted in improved outcomes in advanced RCC for which no effective treatment existed until recently.Areas covered: This article reviews epidemiology, pathology and pathogenesis, diagnosis, clinical staging, prognostic factors and treatment modalities of early stage and advanced RCC.Expert commentary: Although treatment options are expanding rapidly, practicing physicians face considerable challenges in the decision-making process. Therapeutic agents may have unique side effects and unexpected drug interactions. RCC represents one of the major success stories of clinical oncology in recent years and the progress appears to be far from having reached a plateau. We aim to present a comprehensive in-depth review of RCC in an attempt to provide evidence-based recommendations and future perspectives for practicing oncologists.en_US
dc.identifier.doi10.1080/14737140.2016.1222908en_US
dc.identifier.endpage968en_US
dc.identifier.issn1473-7140
dc.identifier.issn1744-8328
dc.identifier.issue9en_US
dc.identifier.pmid27548347en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage955en_US
dc.identifier.urihttps://doi.org/10.1080/14737140.2016.1222908
dc.identifier.urihttps://hdl.handle.net/11454/52400
dc.identifier.volume16en_US
dc.identifier.wosWOS:000383863600010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Review of Anticancer Therapyen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal cell canceren_US
dc.subjectclassificationen_US
dc.subjectdiagnosisen_US
dc.subjecttreatmenten_US
dc.subjecttargeted therapiesen_US
dc.titleRenal cell cancer: overview of the current therapeutic landscapeen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu